In addition, a recent clinical trial used CCL2 expression level as a secondary measure of efficacy for glioblastoma patients' treatment using Salovum egg yolk powder (ClinicalTrials.gov, Identifier: NCT04116138). The gene discussed is CCL2; the disease is glioblastoma.